Biological
Autologous cord blood
Autologous cord blood is a biological therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Withdrawn2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
completed133%
withdrawn267%
Recent Activity
0 active trials
Showing 3 of 3
withdrawnphase_1
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
NCT02551003
completedphase_1
Autologous Cord Blood Cells for Brain Injury in Term Newborns
NCT01649648
withdrawnphase_1
Safety Study of Umbilical Cord Blood To Treat Pediatric Traumatic Brain Injury
NCT01251003
Clinical Trials (3)
Showing 3 of 3 trials
NCT02551003Phase 1
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
NCT01649648Phase 1
Autologous Cord Blood Cells for Brain Injury in Term Newborns
NCT01251003Phase 1
Safety Study of Umbilical Cord Blood To Treat Pediatric Traumatic Brain Injury
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3